{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:19:01Z","timestamp":1790957941937,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.antiviral.2015.06.016","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T21:56:52Z","timestamp":1435183012000},"page":"31-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Benzimidazole analogs inhibit respiratory syncytial virus G protein function"],"prefix":"10.1016","volume":"121","author":[{"given":"Carrie W.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Noah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.antiviral.2015.06.016_b0005","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1086\/516152","article-title":"Animal models of respiratory syncytial virus infection","volume":"25","author":"Byrd","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.016_b0010","unstructured":"Chembridge, 2015. Chembridge corporation: pre-selected diversity libraries for HTS and chemical biology. <http:\/\/www.chembridge.com\/screening_libraries\/diversity_libraries\/> Accessed March 9, 2015."},{"issue":"24","key":"10.1016\/j.antiviral.2015.06.016_b0015","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1128\/JVI.01741-13","article-title":"Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses","volume":"87","author":"Chirkova","year":"2013","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2015.06.016_b0020","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/AAC.48.7.2448-2454.2004","article-title":"Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection","volume":"48","author":"Cianci","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2015.06.016_b0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.antiviral.2015.06.016_b0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.11.3.430","article-title":"Respiratory syncytial virus vaccines","volume":"11","author":"Dudas","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.antiviral.2015.06.016_b0035","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.4049\/jimmunol.176.3.1600","article-title":"Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses","volume":"176","author":"Harcourt","year":"2006","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.antiviral.2015.06.016_b0040","doi-asserted-by":"crossref","first-page":"e74905","DOI":"10.1371\/journal.pone.0074905","article-title":"Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease","volume":"8","author":"Jorquera","year":"2013","journal-title":"PLoS ONE"},{"issue":"25","key":"10.1016\/j.antiviral.2015.06.016_b0045","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1073\/pnas.94.25.13961","article-title":"Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant","volume":"94","author":"Karron","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.antiviral.2015.06.016_b0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/imt.10.53","article-title":"Therapeutic targeting of respiratory syncytial virus G-protein","volume":"2","author":"Kauvar","year":"2010","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.antiviral.2015.06.016_b0055","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s007050050156","article-title":"Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells","volume":"142","author":"Krusat","year":"1997","journal-title":"Arch. Virol."},{"issue":"20","key":"10.1016\/j.antiviral.2015.06.016_b0060","doi-asserted-by":"crossref","first-page":"10710","DOI":"10.1128\/JVI.00986-09","article-title":"Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans","volume":"83","author":"Kwilas","year":"2009","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2015.06.016_b0065","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"Mackman","year":"2015","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.antiviral.2015.06.016_b0070","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1021\/jm500902x","article-title":"Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity","volume":"57","author":"Matharu","year":"2014","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.antiviral.2015.06.016_b0075","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1021\/jm300612z","article-title":"(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection","volume":"55","author":"Moore","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.06.016_b0080","unstructured":"Noah, J.W., Severson, W., Chung, D.H., Moore, B., Jia, F., Xu, X., Maddox, C., Rasmussen, L., Sosa, M.I., Tower, N.A., Ananthan, S., White, E.L., Jonsson, C., Matharu, D.S., Golden, J.E., Prisinzano, T.E., Aube, J., 2010. A cell based HTS approach for the discovery of new inhibitors of RSV. Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD)."},{"issue":"1","key":"10.1016\/j.antiviral.2015.06.016_b0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2006.07.006","article-title":"A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals","volume":"73","author":"Noah","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.016_b0090","unstructured":"Noah, J.W., Severson, W.E., Chung, D.H., Moore, B., Jia, F., Xu, X., Maddox, C., Rasmussen, L., Sosa, M.I., Tower, N.A., Ananthan, S., Evans, C.W., White, E.L., Jonsson, C., Matharu, D.S., Flaherty, D.P., Simpson, D.S., Golden, J.E., Aube, J., 2010. Identification of a series of quinazolinediones as potent, selective, post-entry inhibitors of human respiratory syncytial virus (hRSV) via a cell-based high throughput screen and chemical optimization. Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD)."},{"issue":"2","key":"10.1016\/j.antiviral.2015.06.016_b0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14728210902946399","article-title":"Emerging drugs for respiratory syncytial virus infection","volume":"14","author":"Olszewska","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"8","key":"10.1016\/j.antiviral.2015.06.016_b0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ppul.21244","article-title":"Healthcare costs within a year of respiratory syncytial virus among medicaid infants","volume":"45","author":"Palmer","year":"2010","journal-title":"Pediatric Pulmonol."},{"issue":"1","key":"10.1016\/j.antiviral.2015.06.016_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.healun.2008.10.008","article-title":"Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection","volume":"28","author":"Pelaez","year":"2009","journal-title":"J. Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.antiviral.2015.06.016_b0110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bmcl.2012.11.062","article-title":"Non-benzimidazole containing inhibitors of respiratory syncytial virus","volume":"23","author":"Pryde","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.antiviral.2015.06.016_b0115","doi-asserted-by":"crossref","first-page":"e25468","DOI":"10.1371\/journal.pone.0025468","article-title":"Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998\u20132010","volume":"6","author":"Rebuffo-Scheer","year":"2011","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.antiviral.2015.06.016_b0120","first-page":"358","article-title":"Medication highlights: new recommendations for palivizumab (Synagis)","volume":"33","author":"Ridky","year":"2014","journal-title":"Neonatal Netw."},{"issue":"8","key":"10.1016\/j.antiviral.2015.06.016_b0125","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1128\/JVI.77.8.4609-4616.2003","article-title":"Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection","volume":"77","author":"Schlender","year":"2003","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2015.06.016_b0130","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2032-chloromethyl-2\u2032-deoxy-3\u2032,5\u2032-di-O-isobutyryl-2\u2032-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.antiviral.2015.06.016_b0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bmcl.2006.11.063","article-title":"Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability","volume":"17","author":"Yu","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.antiviral.2015.06.016_b0140","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bmcl.2003.12.072","article-title":"Respiratory syncytial virus inhibitors. Part 2: benzimidazol-2-one derivatives","volume":"14","author":"Yu","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T17:45:42Z","timestamp":1566927942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":28,"alternative-id":["S0166354215001473"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.016","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzimidazole analogs inhibit respiratory syncytial virus G protein function","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}